What did Triomics raise in Series B?

Triomics’ Series B: what happened and why it matters

Triomics, a startup building an AI platform for oncology teams, raised a $22M Series B. The round follows a $15M Series A in 2024, signaling continued investor confidence in the company’s focus on automating data-heavy workflows in cancer care.

The company’s pitch centers on reducing manual administrative and research effort for clinicians and cancer center staff. Rather than targeting a single clinical workflow, the platform is aimed at operational tasks where large amounts of data make processes slow—such as preparing for appointments and supporting clinical-trial related work.

In practical terms, this type of tooling matters because oncology environments often involve fragmented information across systems and heavy coordination among staff. Automating “back office” work can speed up turnaround times for time-sensitive steps, and can also help clinicians spend more effort on direct patient care.

The broader relevance is that Triomics is positioned within the wave of agentic/AI-enabled enterprise software, but with a clear vertical: healthcare and oncology. That verticalization can be crucial for adoption, because buyers typically want workflows that fit existing operational realities (data formats, compliance constraints, and integration needs) rather than generic chat or general-purpose automation.

For investors and the market, the move also suggests that funding appetite remains strong for healthcare-focused AI—especially where the value proposition is measurable in workflow time saved and support for complex tasks like trial matching.